瑞科生物-B2023中期报告

江蘇瑞科生物技術股份有限公司 Jiangsu Recbio Technology Co., Ltd. ( a joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司） Stock Code：2179股份代號 Contents 2Corporate Information6Chairman’s Statement8Financial Highlights9Management Discussion and Analysis38Other Information64Independent Review Report66Interim Condensed Consolidated Statement of Profitor Loss and Other Comprehensive Income67Interim Condensed Consolidated Statement ofFinancial Position69Interim Condensed Consolidated Statement of Changesin Equity71Interim Condensed Consolidated Statement of Cash Flows74Notes to Interim Condensed Consolidated FinancialInformation90Definitions and Glossary of Technical Terms Corporate Information DIRECTORS 1 Executive Directors1 Dr. LIU Yong(Chairman of the Board and General Manager)Dr. CHEN JianpingMr. LI BuMs. CHEN Qingqing 2 Non-Executive Directors2 Dr. HONG KunxueDr. ZHOU HongbinMr. ZHANG JiaxinMr. HU Houwei Independent Non-Executive Directors GAO Feng Mr. LIANG GuodongDr. XIA LijunProfessor GAO FengProfessor YUEN Ming Fai SUPERVISORS Ms. QIAO Weiwei(Chairwoman)Mr. WANG FeizhouMs. QIAN RantingMs. LIU Ping JOINT COMPANY SECRETARIES Ms. CHEN QingqingMs. HO Yin Kwan 1Ms. CHEN Qingqing was appointed as an executive Directoron May 11, 2023.2Mr.ZHAO Hui and Dr.DU Wei resigned as non-executiveDirectorsand members of the Remuneration and AppraisalCommitteeon March 20,2023;Dr.FENG Tao resigned asanon-executive Director and a member of the NominationCommittee on April 3, 2023; Mr. ZHANG Jiaxin and Mr. HUHouwei were appointed as non-executive Directors on May 11,2023. 2023511 20233202023432023511 Corporate Information AUTHORISED REPRESENTATIVES Dr. LIU YongMr. LI Bu AUDIT COMMITTEE Dr. XIA Lijun(Chairman)Professor YUEN Ming FaiDr. ZHOU Hongbin REMUNERATION AND APPRAISAL COMMITTEE GAO Feng Professor YUEN Ming Fai(Chairman)Dr. XIA LijunMr. LIANG GuodongProfessor GAO FengMr. LI Bu NOMINATION COMMITTEE GAO Feng Dr. LIU Yong(Chairman)Professor GAO FengMr. LIANG GuodongDr. XIA Lijun H H SHARE REGISTRAR 1831717121716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17th FloorHopewell Centre183 Queen’s Road EastWan ChaiHong Kong Corporate Information HEAD OFFICE AND REGISTERED OFFICE IN THE PRC No. 888 Yaocheng AvenueMedical High-tech DistrictTaizhou CityJiangsu Provincethe PRC 888 PRINCIPAL PLACE OF BUSINESS IN HONG KONG 40th Floor, Dah Sing Financial CentreNo. 248 Queen’s Road EastWanchaiHong Kong 24840 COMPLIANCE ADVISER 117 Soochow Securities International Capital LimitedLevel 17, Three Pacific Place1 Queen’s Road EastHong Kong PRINCIPAL BANK 29310 China Merchants Bank Co., Ltd.Taizhou BranchBuilding 10, No. 293, Gulou South RoadHailing DistrictTaizhou CityJiangsu Province, the PRC HONG KONG LEGAL ADVISOR 27 Clifford Chance27/F, Jardine HouseOne Connaught PlaceHong Kong Corporate Information PRC LEGAL ADVISOR 2022-31 Zhong Lun Law Firm22-31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijing, the PRC AUDITOR 97927 Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong www.recbio.cn COMPANY’S WEBSITEwww.recbio.cn STOCK CODE 21792179 Chairman’s Statement Dear Shareholders, I would like to extend my sincere gratitude to all of you for yourgreatsupport for the Group’s business and development!Thecurrent global capital market turmoil poses a challenge and anopportunity for Recbio. Steppinginto 2023,the Company adheres to its mission of“protecting human health with best-in-class vaccines”, focusingonits strategic pipeline,accelerating the R&D of key varietiesandpreparing for their commercial application.Constantlyimproving its technology platform and management capabilitiesandenhancing its development momentum,the Company hasmadesignificant progress in all aspects of its operation andmanagement. 2023 HPVREC603III1824IIIREC603HPV REC603, a recombinant HPV 9-valent vaccine of the Company,is undergoing a phase III efficacy trial in three provinces, namelyHenan, Yunnan and Shanxi. To date, we have completed the visitof the 18th month and are conducting the visit and observation ofthe 24th month. The design of the phase III clinical trial protocolis highly consistent with the requirements and recommendationsof the newly enactedTechnical Guidelines for the Clinical TrialsofHuman Papillomavirus Vaccines(for Trial Implementation) ,with a leading sample size and notable advantages in the clinicalsite. We are more confident than ever to achieve the early marketlaunch of REC603 and to satisfy the urgent demand for the HPV9-valent vaccine in the global market. REC6102Shingrix®307REC610I/IIIREC610BFA01VZVE(gE)CD4+T1%REC610 REC610,a novel adjuvanted recombinant shingles vaccine,commenced its first-in-human Shingrix®active controlled clinicaltrial in the Philippines in February. Currently, the clinical trial